CD40 expression identifies a prognostically favourable subgroup of diffuse large B-cell lymphoma

Leukemia and Lymphoma

Volumn 48, Issue 9, 2007, Pages 1774-1779

  Linderoth, Johan ^a   Ehinger, Mats ^a   Jerkeman, Mats ^a   Bendahl, Pär Ola ^a   Åkerman, Måns ^a   Berglund, Mattias ^b   Enblad, Gunilla ^b   Erlanson, Martin ^c   Roos, Göran ^c   Cavallin Ståhl, Eva ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

Author keywords

CD4; CD40; CD8; DLBCL; GC phenotype; Prognosis

Indexed keywords

CD23 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROTEIN BCL 6; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GERMINAL CENTER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME; T LYMPHOCYTE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD40; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PROGNOSIS;

EID: 34548593571     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701494520     Document Type: Article

References (26)

1. Shipp, M. A., Harrington, D. P., Anderson, J. R., Armitage, J. O., Bonnadonna, G. and Brittinger, G. (1993) A predictive model for aggressive NHL. The International Non-Hodgin's Lymphoma Prognostic Factors Project. N Engl J Med, 329, pp. 987-994.
2. Alizadeh, A. A., Eisen, M. B., Davis, R. E., Lossos, I. S. and Rosenwald, A. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403, pp. 503-511.
3. Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E. and Fisher, R. I. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med, 346, pp. 1937-1947.
4. Hans, C. P., Weisenburger, D. D., Greiner, T. C., Gascoyne, R. D., Delabie, J. and Ott, G. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103, pp. 275-282.
5. Linderoth, J., Jerkeman, M., Cavallin-Stahl, E., Kvaloy, S. and Torlakovic, E. (2003) Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: A Nordic Lymphoma Group Study. Clin Cancer Res, 9, pp. 722-728.
6. Schultze, J. L., Cardoso, A. A., Freeman, G. J., Seamon, M. J., Daley, J. and Pinkus, G. S. (1995) Follicular lymphomas can be induced to present alloantigen efficiently: A conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci USA, 92, pp. 8200-8204.
7. Kato, K., Cantwell, M. J., Sharma, S. and Kipps, T. J. (1998) Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest, 101, pp. 1133-1141.
8. Khanna, R., Cooper, L., Kienzle, N., Moss, D. J., Burrows, S. R. and Khanna, K. K. (1997) Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells. J Immunol, 159, pp. 5782-5785.
9. Lippman, S. M., Spier, C. M., Miller, T. P., Slymen, D. J., Rybski, J. A. and Grogan, T. M. (1990) Tumor-infiltrating T-lymphocytes in B-cell diffuse large cell lymphoma related to disease course. Mod Pathol, 3, pp. 361-367.
10. Stopeck, A. T., Gessner, A., Miller, T. P., Hersh, E. M., Johnson, C. S. and Cui, H. (2000) Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma. Clin Cancer Res, 6, pp. 3904-3909.
11. Rimsza, L. M., Roberts, R. A., Miller, T. P., Unger, J. M., LeBlanc, M. and Braziel, R. M. (2004) Loss of MHC class II gene and protein expression in diffuse large B cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival irrespective of other prognostic factors: A follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood, 103, pp. 4251-4258.
12. Ansell, S. M., Stenson, M., Habermann, T. M., Jelinek, D. F. and Witzig, T. E. (2001) Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J Clin Oncol, 19, pp. 720-726.
13. Kroft, S. H., McKenna, R. W. and Aquino, D. B. (2001) Prognostic significance of tumour-infiltrating T lymphocytes and T-cell subsets in de novo diffuse large B-cell lymphoma: A multiparameter flow cytometry study. Br J Haematol, 112, pp. 945-949.
14. Altman, D. G. (1991) Practical Statistics for Medical Research, p. 394. Chapman & Hall, London
15. Sasaki, T., Hoshida, Y., Xu, J. X., Tomita, Y., Sakane-Ishikawa, E. and Fujita, S. (2005) Prognostic significance of CD40 expression in malignant lymphoma developing in rheumatoid arthritis. J Cancer Res Clin Oncol, 131, pp. 797-802.
16. Vyth-Dreese, F. A., Boot, H., Dellemijn, T. A., Majoor, D. M., Oomen, L. C. and Laman, J. D. (1998) Localization in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin's lymphoma. Immunology, 94, pp. 580-586.
17. van Kooten, C. and Banchereau, J. (2000) CD40-CD40 ligand. J Leukoc Biol, 67, pp. 2-17.
18. DiSanto, J. P., Bonnefoy, J. Y., Gauchat, J. F., Fischer, A. and Basile, G de Saint (1993) CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM. Nature, 361, pp. 541-543.
19. Basso, K., Klein, U., Niu, H., Stolovitzky, G. A. and Califano, A. (2004) Tracking CD40 signaling during germinal center development. Blood, 104, pp. 4088-4096.
20. Ridge, J. P., Rosa, F Di and Matzinger, P. (1998) A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature, 393, pp. 474-478.
21. Bennett, S. R., Carbone, F. R., Karamalis, F., Flavell, R. A., Miller, J. F. and Heath, W. R. (1998) Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature, 393, pp. 478-480.
22. Schoenberger, S. P., Toes, R. E., van der Voort, E. I., Offringa, R. and Melief, C. J. (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40 - CD40L interactions. Nature, 393, pp. 480-483.
23. French, R. R., Taraban, V. Y., Crowther, G. R., Rowley, T. F., Gray, J. C. and Johnson, P. W. (2007) Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. Blood, 109, pp. 4810-4815.
24. Ritchie, D. S., Yang, J., Hermans, I. F. and Ronchese, F. (2004) B-Lymphocytes activated by CD40 ligand induce an antigen-specific anti-tumour immune response by direct and indirect activation of CD8(+) T-cells. Scand J Immunol, 60, pp. 543-551.
25. Yang, Z. Z., Novak, A. J., Stenson, M. J., Witzig, T. E. and Ansell, S. M. (2006) Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood, 107, pp. 3639-3646.
26. Vonderheide, R. H. (2007) Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res, 13, pp. 1083-1088.